# Probiotic Constipation Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/probiotic-constipation-meta-analysis-evidence-review
Category: evidence-review
Summary: Probiotic Constipation Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are sy
Last reviewed: 2026-05-21
Reviewed by: Migaku Evidence Review
# Probiotic Constipation Meta-analysis: What the Evidence Says

## Quick Answer

Probiotic Constipation Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, guideline, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 guideline.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Commentary: The effect of probiotics on the diarrhea and constipation outcomes in children: an umbrella review of systematic reviews and meta-analyses | systematic review | 1 | 2026-02-23 | 10.3389/fnut.2026.1762445 |
| Clinical Guidance and Practical Recommendations for Probiotic Use in Patients With Irritable Bowel Syndrome, Functional Constipation, and Clostridioides difficile Infection Considering Sex-based Differences | guideline | 2 | 2026-04-30 | 10.5056/jnm25221 |

## What The Sources Report

- The authors did a good job of summarizing a large body of evidence, and their conclusion that probiotics help with childhood diarrhea agrees with the general scientific opinion. [Peng Yue (2026); evidence level 1]
- As a result, the total sample size is inflated, which narrows the confidence intervals for the summary effect estimate. [Peng Yue (2026); evidence level 1]
- This review summarizes the current concepts of probiotics and evaluates evidence supporting their use in patients with lower GI disorders, with a focus on potential sex-related differences. [Kim Yong Sung (2026); evidence level 2]
- Saccharomyces, Lactobacillus Bifidobacterium Clostridium difficile 7 This review was conducted to summarize and interpret the current evidence on probiotics on IBS, FC, and CDI in terms of sex differences. [Kim Yong Sung (2026); evidence level 2]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For probiotic constipation meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Peng Yue (2026). Commentary: The effect of probiotics on the diarrhea and constipation outcomes in children: an umbrella review of systematic reviews and meta-analyses. DOI: 10.3389/fnut.2026.1762445. PMCID: PMC12968263. PMID: 41809106. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12968263/
- Kim Yong Sung (2026). Clinical Guidance and Practical Recommendations for Probiotic Use in Patients With Irritable Bowel Syndrome, Functional Constipation, and Clostridioides difficile Infection Considering Sex-based Differences. DOI: 10.5056/jnm25221. PMCID: PMC13071424. PMID: 41807013. License: https://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0 This is an open-access .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13071424/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.